Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4922 - Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR trial

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy;  Surgical Oncology

Tumour Site

Melanoma

Presenters

Stephanie Blankenstein

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

S. Blankenstein1, M.W. Rohaan2, W.M.C. Klop3, B. van der Hiel4, B. van de Wiel5, D. Peeper6, A.C.J. van Akkooi1, J.B.A.G. Haanen7

Author affiliations

  • 1 Surgical oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 2 Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 3 Head And Neck Surgery And Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 4 Nuclear Medicine, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 5 Pathology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 6 Molecular Oncology And Immunology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 7 Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
More

Resources

Abstract 4922

Background

The aim of this trial is to evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib and trametinib (BRAF and MEK inhibitor respectively) to allow radical surgical resection in patients with unresectable BRAF-mutated, locally advanced stage III or oligometastatic stage IV melanoma.

Methods

A total of 25 patients with BRAF-mutated, unresectable locally advanced stage III or oligometastatic stage IV (≤3 metastases) melanoma will be treated with dabrafenib and trametinib for 8 weeks. Response evaluation by positron emission tomography/computed tomography (PET/CT) will occur at 2 and 8 weeks. If sufficient downsizing occurs, surgical resection will be performed. Biopsies for translational research will be taken at baseline and 2 weeks. The dissection specimen will be stored at 8 weeks.

Results

Currently 17 patients have been included. Of these, 2 patients showed PD upon treatment and did not proceed to surgery. In 14/15 (93%) patients resection was possible after neoadjuvant treatment, of which 13 (93%) were R0 resections. Median follow-up time is 22 months with a median recurrence free survival of 9 months in patients undergoing surgery. The 1-year overall survival (OS) was 88% and 2-year OS 59%. Median OS was not reached. Metabolic response rates (RR) on PET/CT at 8 weeks were: 4 (24%) CR, 11 (65%) PR, 0 (0%) SD, 2 (12%) PD. Pathologic RR differed: 6 (35%) CR, 5 (29%) PR, 3 (19%) SD, 0 (0%) PD and in 3 patients (18%) no pathologic response was measured, since no resection was performed. Most patients (82%) experienced any toxicity, of which the majority (64%) was grade 1 and the most common reported toxicity was fever. Grade 3 toxicity occurred in 2 patients (12%).

Conclusions

Neoadjuvant dabrafenib and trametinib shows to be a potent cytoreductive treatment, allowing radical resection of metastases in 13/17 (76%) patients with prior unresectable locally advanced melanoma. Patients with no recurrence remained disease-free for a prolonged period of time. If there was recurrent disease, this usually occurred within months after surgery and this may present an opportunity for further tailored adjuvant therapy.

Clinical trial identification

EudraCT: 2013-002616-28

Legal entity responsible for the study

Netherlands Cancer Institute, Amsterdam, The Netherlands.

Funding

Netherlands Cancer Institute and Novartis.

Editorial Acknowledgement

Disclosure

D. Peeper: Research support: BMS. A.C.J. van Akkooi: Consulting or advisory role: Amgen, Novartis, MSD Oncology, Merck Research funding: Amgen, Novartis; Travel, accomodations, expenses: Amgen, Novartis, MSD Oncology, Merck. J.B.A.G. Haanen: Compensation to NKI for advisory roles: BMS, Merck, Roche, Neon Therapeutics, Pfizer, Ipsen; Grants to NKI: BMS, Merck, Novartis, Neon Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.